Of note, in several independent cohorts of breast cancer patients, the ISG MX Dynamin-Like GTPase 1 (MX1) was shown to be upregulated following anthracycline-based therapy and to predict clinical response to treatment [3]. Here, MX1 is linked to breast carcinoma.